News of Note—Roche's blockbuster licensing deal; FibroGen's roxadustat application and more

Roche's gene therapy licensing deal with Sarepta headlines today's news of note. (Pixabay)

> In a blockbuster licensing deal, Roche is paying Sarapta more than $1 billion up front for ex-U.S. rights to a Duchenne muscular dystrophy gene therapy candidate. Under the agreement, Sarepta is eligible for up to $1.7 billion in milestones and royalties. The deal comes right after Roche built up its gene therapy presence through its Spark Therapeutics buyout. FierceBiotech story 

> FibroGen has submitted its AstraZeneca-partnered anemia med roxadustat to the FDA. The med scored an approval in China back in August. Release 

> Pfizer inked a licensing deal with Theravance Biopharma, paying $10 million up front for global rights to the company's preclinical JAK inhibitor candidates. Under the agreement, Theravance is eligible for up to $240 million in milestones, plus potential royalties. Release


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

> BioMarin submitted its hemophilia A gene therapy candidate valoctocogene roxaparvovec to the FDA. Meanwhile, the biotech said the European Medicines Agency accepted its application, and the drug's review at that agency will start in January. Release | Release

> Leo Pharma has sold a group of anti-hemorrhoid and dermatology drugs to Karo Pharma for €90 million ($100 million). Leo intends to focus more on innovative meds, and CFO Anders Kronborg said in a statement the “well-established portfolio will be better served by Karo Pharma and its team.” Release 

> AstraZeneca scored approval for its triple-combination therapy for COPD in China, where there are nearly 100 million patients. Regulators in the U.S. and Europe are reviewing the med, which won approval as Breztri Aerosphere in Japan back in June. Release 

> Johnson & Johnson inked a buyout of Taris Biomedical, getting access to the private biotech’s drug delivery technology for bladder diseases. Financial terms weren’t disclosed. Release 

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.